STEMTECH CORPORATION Stock Price, News & Analysis

Stemtech Corporation (OTCQB: STEK) announced a strategic joint venture with Lightway Ventures to establish Stemtech Asia (Hong Kong) to distribute Stemtech products in China, subject to final funding and regulatory approvals.

The JV equity is planned as 51% Stemtech / 49% Lightway with profits split 50/50. Lightway intends to finance the JV and pursue prime placement with a national e-commerce retailer and a leading pharmacy chain, targeting flagship rollouts in Shanghai and Beijing and a quick ramp in 2026. Stemtech will supply products and science, with eventual plans to manufacture in China. The release cites China’s population of ~1.4 billion and a nutraceutical market projection of $109 billion by 2033.

Stemtech Corporation (OTCQB:STEK) and Innoventure Dynamic LLP formed a joint venture, Stemtech HealthSciences India Pvt Ltd, announced October 23, 2025, to enter India and GCC markets with plant-based stemceutical products.

Key specifics: STEK retains 51% ownership, Innoventure 49%, profits split 50/50, and financing provided by India investors. Distribution targets include a 5,500+ outlet organized pharmacy anchor, access to 1.24M+ retail chemists, an initial priority of ~80,000 doors within 24 months, and a focus on e-commerce and professional recommendations in India’s ~$32B nutraceutical market.

Stemtech Corporation (OTCQB:STEK) announced a joint venture with Innoventure Dynamic LLP to form Stemtech HealthSciences India Private Limited (SHIPL) dated October 23, 2025. Stemtech will hold 51% and Innoventure 49% of the JV; India startup funding will be provided entirely by Innoventure.

John W. Meyer will serve as Managing Director for SHIPL. The JV will distribute all Stemtech product lines—stemceuticals, skin care, oral care and pet products—with an eventual plan to manufacture in India and target a population of over 1.4 billion.

Stemtech (OTCQB:STEK) announced on October 20, 2025 that core products are now available for shipment after supply delivery and manufacturing challenges delayed order fulfillment. The company cited tariffs and capital constraints on internationally sourced raw materials as causes of prior backorders.

U.S. backorders are being cleared, inventory for Mexico is being produced and will ship shortly, and shipments to Canada and Ecuador are en route. Management highlighted market demand with a $4.6 billion stem cell market in 2024 and a projected $30 billion market by 2030.

Stemtech Corporation (OTC: STEK) announced an exclusive distribution licensing agreement with Energy International Development Co., Ltd. to sell Stemtech products in Taiwan, R.O.C. on October 9, 2025. The company said products are already manufactured in Taiwan and will be distributed through the licensee's retail networks. Management described the licensing model as a way to generate revenue via licensing fees and manufacturing without the costs of direct operations, while the licensee projects strong growth in the territory.

The announcement emphasizes market expansion, local manufacturing and a low‑overhead licensing strategy to monetize Stemtech's stem cell nutrition products in Taiwan.

Stemtech Corporation (OTCQB:STEK) has announced a significant collaboration with renowned clinical physician Dr. Sabine Hazan, MD to conduct clinical trials on their RCM System of stem cell nutrition products. Dr. Hazan, known for her expertise in gastroenterology and natural remedies, will evaluate the effects of Stemtech's products on the microbiome.

The research will focus on Stemtech's three key products: stemrelease3™, StemFlo Advanced®, and MigraStem®. The company has reported cumulative sales of over $600 million USD with less than 2% returns. Stemtech currently operates in the United States, Mexico, Ecuador, Canada, and Taiwan.

This partnership aims to document the benefits of Stemtech's natural, plant-based approach to stem cell nutrition and inflammation management through transparent, data-driven clinical trials.

Stemtech Corporation (OTCQB:STEK) has launched a new 'Well-Aging' video series featuring Dr. Lizette Leos, MD, focusing on the company's plant-based nutraceutical products. The series covers topics like cellular regeneration, biohacking, and aging science, with content available in English, Spanish, Chinese, and French. Dr. Leos, who has led Stemtech's science and training since 2017, will also provide bi-weekly publications on biotechnology and longevity insights. The company emphasizes its unique position as a pioneer in stem cell nutrition with its RCM System, OraStem toothpaste, Cellect One skincare products, and StemPets supplements. The content aims to educate viewers about natural cellular regeneration enhancement through lifestyle choices and supplementation.

Stemtech Corporation (OTCQB:STEK) has announced the launch of StemPets™, a revolutionary pet nutraceutical supplement, available in the U.S. starting June 2025 and in Mexico two weeks later. The product, designed for dogs and cats, is a 100% plant-based anti-aging and longevity formula featuring anacardic acid as its key ingredient.

The company holds exclusive distribution rights for this AAFCO-registered compound. StemPets™ aims to provide benefits including increased energy levels, shinier coat, healthier skin, better digestion, and improved joint health. This launch represents Stemtech's strategic entry into the pet wellness market, which is projected to exceed $500 billion globally by 2030.

Stemtech (STEK) has announced strategic leadership changes and plans to launch StemPets™, their new pet health product line, in early Q2 2025. The company aims to capture a share of the global pet care market, projected to reach $303 billion by 2027.

Key leadership appointments include:

• Alejandro Carrillo promoted to VP of Global Operations after 10 years with the company
• Srilakshmi Vadlapatla appointed as Global Accounts Manager, set to become CFO
• Manuel Ramirez Garcia joins as Director of Global Sales & Field Development

The company announced the departure of James S. Cardwell from his CFO position. These appointments align with Stemtech's strategy to expand its stem cell nutrition business globally and enter the pet healthcare market.